Why Comprehensive Analytical Services Are Core To The Future Of Antibody-Drug Conjugates

By Junhua Zhu and Brent Kennedy, Catalent

Antibody-drug conjugates (ADCs) combine antibodies, linkers, and cytotoxic payloads into highly complex therapeutic systems that require extensive analytical characterization to understand structure, stability, and function. Their performance depends on the interaction of multiple variables, including drug-to-antibody ratio (DAR), linker stability, and higher-order structure. Each of these attributes can influence efficacy, safety, manufacturability, and regulatory outcomes, making ADC development more analytically demanding than traditional biologics or small molecules.

A central challenge in ADC development is balancing speed with depth of characterization. Early development programs often accelerate timelines to reach clinical evaluation quickly, but limited analytical insight at this stage can lead to downstream issues such as instability, aggregation, manufacturing challenges, or regulatory delays. Gaps in early understanding of critical quality attributes frequently resurface later, requiring additional work that extends timelines and increases cost.

To address this, organizations are adopting phase-appropriate, integrated analytical strategies that evolve alongside the molecule. Early stages focus on broad structural and stability characterization to identify risks, while later stages emphasize quantitative assessment, method validation, and regulatory readiness. Techniques such as LC-MS, peptide mapping, CD, SEC-MALS, and bioassays support a more complete understanding of product behavior across development stages.

This lifecycle approach ensures continuity of knowledge, reduces rework, and improves decision-making. By embedding analytics early and maintaining it throughout development, ADC programs can better manage complexity, reduce risk, and support more efficient progression from discovery to commercialization.